4D Therapeutics

4D Molecular Therapeutics (4DMT) is a clinical-stage biopharmaceutical company pioneering the development of optimized gene therapy products using its proprietary Therapeutic Vector Evolution platform. The company utilizes directed evolution to create customized adeno-associated virus (AAV) vectors designed to overcome the limitations of first-generation gene therapies, such as pre-existing immunity and inefficient delivery. 4DMT's diverse pipeline targets high-value indications in ophthalmology, pulmonology, and cardiology. Their lead candidate, 4D-150, is currently in mid-stage clinical trials for major retinal diseases including wet age-related macular degeneration and diabetic macular edema.